Skip to main content
. Author manuscript; available in PMC: 2022 May 24.
Published in final edited form as: Nanomedicine. 2021 Nov 4;40:102476. doi: 10.1016/j.nano.2021.102476

Table 4.

Activities/concentrations of biomarkers for lung disease.

Biomarker Activity/concentration
Apparently healthy human subjects [mol L−1]
Activity/concentration
Mild asthma patients [mol L−1]
ADAM 33 < 10−16 2.6 × 10−15–2.0 × 10−12
Arginase 3.6 × 10−15–5.0 × 10−15 1.2 × 10−12–6.0 × 10−12
CCL20 2.8 × 10−14–2.4 × 10−12 8.0 × 10−12–1.3 × 10−11
Granzyme B < 10−16 4.6 × 10−14–4.0 × 10−12
Interleukin-6 < 10−15 1.5 × 10−10–5.0 × 10−9
Matrix-metalloproteinase-8 2.8 × 10−13–7.6 × 10−11 2.6 × 10−16–1.2 × 10−14
Neutrophil elastase < 10−16 9.0 × 10−16–6.2 × 10−14